Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration

Trial Profile

A Phase III Double-Blind, Parallel Group, Multicenter Study to Compare the Efficacy and Safety of Xlucane Versus Lucentis® in Patients With Neovascular Age-Related Macular Degeneration

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2019

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Choroidal neovascularisation; Wet age-related macular degeneration
  • Focus Registrational; Therapeutic Use
  • Acronyms XPLORE
  • Sponsors Xbrane
  • Most Recent Events

    • 18 Jan 2019 According to a Xbrane media release, applications to additional countries other than the U.S. are being submitted continuously during January and February 2019.
    • 18 Jan 2019 According to a Xbrane media release, company has for the Xplore study contracted the global CROn Syneos Health, and company will communicate regarding the continuation of the study at the following milestones: first patient in, last patient entered, overall results on the primary efficacy measure and clinical study report.
    • 18 Jan 2019 According to a Xbrane media release, company recieved approval from the FDA and the Central Ethics Committee to initiate this study.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top